SciELO - Scientific Electronic Library Online

 
vol.22 número6Sgarbossa criteria: is it time for an update?Percutaneous renal denervation using balloon catheter in patients with resistant hypertension índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Cardiología

versão impressa ISSN 0120-5633

Resumo

ARISTIZABAL, Julián M. et al. Those "other" bradycardias. Rev. Colomb. Cardiol. [online]. 2015, vol.22, n.6, pp.298-304. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2015.07.006.

Bradycardia is a common finding in the context of hospitalized patients. Sometimes it is incidentally detected and its clinical implications are minimized. But sometimes it is associated with the presence of symptoms or hemodynamic compromise in patients who warrant further intervention. The etiology of the bradycardia is not always easy to determine and it is not surprising that many studies are initiated in order to clarify the reason for the situation. Clinicians are familiar with the pharmacological and adverse effects of various drugs we use every day. Despite this, there are many drugs with potential to develop bradycardia in response to a less known pharmacological properties or effects related to rare but certainly significant effects. The aim of this review is to explain the pharmacological properties and clinical impact of some substances that have been associated with bradycardia, beyond which we all know, in order to target interventions to be performed in patients with pharmacological and reversible causes of bradycardia.

Palavras-chave : Arrhythmias; Pharmacology; Sinoatrial node.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )